Introduction: Rapid organism identification (ID) and antimicrobial susceptibility testing 34 (AST) along with antibiotic stewardship (ASP) are critical to appropriate treatment. We 35 sought to capture time for bacterial culture and initiation of appropriate therapy for 36 patients, from 2017 (without MALDI-TOF/Vitek 2 and ASP) and 2018 (with MALDI-37
time periods (2017 and 2018) were eligible when one culture type was positive (i.e. 106 urine culture positive without blood culture positive) for urine and sputum cultures. BSI 107 could have more than one site with positive isolates. 108
Antimicrobial Stewardship. For the 2017 time period (control group), limited ASP was 109 available from staff pharmacists without dedicated ASP personnel. Staff pharmacists 110
were expected to make interventions as part of their normal workflow. In 2018, 111 dedicated ASP personnel were hired providing robust ASP for all CHI Health hospitals 112 (0.5 FTE ID physician and 2.5 FTE ASP pharmacist) and they replaced staff 113 pharmacist's interventions. All ASP pharmacists monitored patients through TheraDoc 114 and consulted the ID clinician for all antimicrobial recommendations. ASP pharmacists 115
were available during normal work hours (8-4:30) and made recommendations on 116 patients receiving empiric therapy with carbapenems, daptomycin, double coverage, 117 (double anaerobic coverage), all C. difficile positive patients, and all S. aureus 118 bacteremias. Since both ASP infectious diseases physician and pharmacists made 119 antimicrobial recommendations to primary care physicians (PCPs), other types of 120 recommendations were suggested including ID consult, TEE, and length of therapy as 121 examples. Both years utilized Biofire BCID (Biofire Diagnostics, Salt Lake City, UT) for 122 rapid detection system on all positive blood cultures. However, in 2018 laboratory 123 technicians increased their daily time frame when Biofire was reported for positive blood 124 cultures (7 am-10 pm). All Biofire results were paged to ASP team. The ASP 125 pharmacist kept the Biofire pager (7-5) and then handed it off to the on-call ID fellow 126 overnigh and weekends. In 2017, Biofire results were reported during normal laboratory 127 hours (7 am -5 pm) and were reviewed by the staff pharmacists as part of an inbasketwork queue in EPIC. ASP pharmacists were available five days/week and used 129 
Results: 155
In the control group (2017), a total of 77 patients (27 blood isolates, 25 sputum, 156 and 25 urine isolates) were retrospectively enrolled between March-May 2017. In the 157 MALDI-TOF/Vitek 2 group, a total of 77 patients (28 blood isolates, 24 sputum, and 25 158 urine isolates) were concurrently enrolled in the same time frame in 2018. Mean (± SD) 159 patient age and Charlson Comorbidity Index (CCI) were not different between the two 160 groups (Table 1) . Additionally, patients were admitted to the intensive care unit 31% in 161 2017 and 32% in 2018, respectively. Microorganisms isolated included 10 (6.5%) that 162 were polymicrobial and the remaining were monomicrobial isolates. The most common 163 single isolate included E. coli (30%), methicillin-sensitive S. aureus (MSSA) (9%), S. 164 pneumoniae (8%), and P. aeruginosa (7%). There were no significant differences in the 165 number of isolates in the study from 2017 compared to 2018. The most common sites 166 of infection from patients in both years included urine (69, 45%), lung (55, 38%), and 167 skin (10, 6.5%). would show a significant benefit to the care of infected patients now that there are more 238 ASP pharmacists (3 covering CHI Health) and an ID physician with 0.5 FTE devoted to 239 ASP across all hospitals in the health system. 240
However, there are limits associated with this study. A lack of patient 241 randomization in the quasi-experimental study may not take into account changes in 242 standard of care from the previous year, which could impact LOS. To our knowledge,both years incorporated Biofire BCID and there were no significant changes in standard 244 of care except the introduction of the ASP team to make antimicrobial 245 recommendations. The study periods were selected to minimize bias associated with 246 medical residents and fellows at our academic medical center. This study excluded 247 patients transferred into our regional hospital so all antimicrobials administration times 248 were in-hospital times and not from administrations prior to admission. The effect of 249 ASP was not directly identified in the stepwise multiple regression analysis. However, 250 length of antimicrobials was identified as the primary factor associated with LOS, and 251 ASP team did have an impact on this variable. By making appropriate antimicrobial 252 recommendations, the ASP team impacted length of therapy and indirectly (probably) 253 impacted LOS. It would be of interest to repeat this study from all CHI Health hospitals 254 in Nebraska to determine the effect of ASP team and MALDI-TOF/Vitek 2 would have 255 on these community hospitals in addition to this report since the centralized laboratory 256 receives these specimens as far away as Kearney, NE (186 miles). 257
In conclusion, use of ASP and MALDI-TOF/Vitek 2 rapid identification and AST 258 demonstrated for urine, blood, and sputum cultures a significant reduction in time to 259 isolate identification and AST results, which translated to significant reduction in 260 antibiotic length of therapy and hospital LOS. Isolates from: 
E. cloacae E. coli
Klebsiella spp.
S. pneumoniae
Proteus spp.
Pseudomonas spp.
Stenotrophomonas spp. 
